咨询客服 咨询客服

Body Composition and Leptin/Ghrelin Levels during Lenvatinib for Thyroid Cancer

Abstract:
Weight loss is one of the most frequent adverse events during treatment with multikinase inhibitors, but scanty data are available on its extent and characteristics. This is the first assessment of the body composition by bioelectrical impedance analysis and of circulating leptin and ghrelin levels, in patients with advanced thyroid cancer before and at regular intervals during treatment with the tyrosine kinase inhibitor lenvatinib. Body mass index (BMI) decreased in all patients, with an average ∆ reduction of –6.4, –9.8, and –15.3% at 3, 6, and 12 months of treatment, respectively. Interestingly, in most patients, after the first year of treatment, BMI remained stable. In all patients, fat mass (FM) reduced more than fat-free mass, the highest decrement being of –60 and –16%, respectively. A decrease in the body cell mass, a parameter mainly due to muscle tissue, was observed only in patients with a vast baseline muscular mass. Total body water decreased in parallel to BMI. During treatment, leptin tightly paralleled the decrease of BMI values, consistent with the decrease in FM, whereas ghrelin levels increased upon BMI decrease. The loss of the FM accounts for the largest portion of BMI reduction during lenvatinib treatment. The increase in ghrelin could account for the BMI stabilization observed after 1 year of treatment. Nevertheless, oral nutritional supplements should be given as early as possible and athletic patients should be encouraged to maintain physical activity. In some circumstances, parenteral nutrition is required for the rehabilitation of these patients.
Author Listing: Simone De Leo;Carla Colombo;Marta Di Stefano;Antonella Dubini;Silvia Cozzi;Luca Persani;Laura Fugazzola
Volume: 9
Pages: 1 - 10
DOI: 10.1159/000504048
Language: English
Journal: European Thyroid Journal

European Thyroid Journal

EUR THYROID J

影响因子:4.3
是否综述期刊:否
是否OA:否
是否预警:不在预警名单内
发行时间:-
ISSN:2235-0640
发刊频率:-
收录数据库:SCIE/Scopus收录
出版国家/地区:Switzerland
出版社:Karger

期刊介绍

The 'European Thyroid Journal' publishes papers reporting original research in basic, translational and clinical thyroidology. Original contributions cover all aspects of the field, from molecular and cellular biology to immunology and biochemistry, from physiology to pathology, and from pediatric to adult thyroid diseases with a special focus on thyroid cancer. Readers also benefit from reviews by noted experts, which highlight especially active areas of current research. The journal will further publish formal guidelines in the field, produced and endorsed by the European Thyroid Association.

《欧洲甲状腺杂志》发表了报告基础、转化和临床甲状腺学原创研究的论文。原始贡献涵盖了该领域的所有方面,从分子和细胞生物学到免疫学和生物化学,从生理学到病理学,从儿童到成人甲状腺疾病,特别关注甲状腺癌。读者还受益于著名专家的评论,其中突出了当前研究的特别活跃的领域。该杂志将进一步出版该领域的正式指南,由欧洲甲状腺协会制作并认可。

年发文量 70
国人发稿量 9
国人发文占比 12.5%
自引率 4.7%
平均录取率 -
平均审稿周期 -
版面费 -
偏重研究方向 Medicine-Endocrinology, Diabetes and Metabolism
期刊官网 https://www.karger.com/Journal/Home/255331
投稿链接 https://www.manuscriptmanager.net/sLib/v4/login.php?paramScreen=i1WBpL4SBHSx7800v5v3oorFRtjWCi4SoTILhe0lqLo=

质量指标占比

研究类文章占比 OA被引用占比 撤稿占比 出版后修正文章占比
84.29% 100.00% 0.00% 1.96%

相关指数

影响因子
影响因子
年发文量
自引率
Cite Score

预警情况

时间 预警情况
2025年03月发布的2025版 不在预警名单中
2024年02月发布的2024版 不在预警名单中
2023年01月发布的2023版 不在预警名单中
2021年12月发布的2021版 不在预警名单中
2020年12月发布的2020版 不在预警名单中

JCR分区 WOS分区等级:Q2区

版本 按学科 分区
WOS期刊SCI分区
(2021-2022年最新版)
ENDOCRINOLOGY & METABOLISM Q1

中科院分区

版本 大类学科 小类学科 Top期刊 综述期刊
医学
3区
ENDOCRINOLOGY & METABOLISM
内分泌学与代谢
3区
2021年12月
基础版
医学
3区
ENDOCRINOLOGY & METABOLISM
内分泌学与代谢
3区
2021年12月
升级版
医学
4区
ENDOCRINOLOGY & METABOLISM
内分泌学与代谢
4区
2020年12月
旧的升级版
医学
4区
ENDOCRINOLOGY & METABOLISM
内分泌学与代谢
4区
2022年12月
最新升级版
医学
2区
ENDOCRINOLOGY & METABOLISM
内分泌学与代谢
2区